{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:19:37Z","timestamp":1792804777933,"version":"4.5.0"},"reference-count":104,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Children\u2019s Hospital of Eastern Ontario","award":["2096"],"award-info":[{"award-number":["2096"]}],"id":[{"id":"https:\/\/ror.org\/05nsbhw27","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Lois Hole Hospital for Women","award":["2096"],"award-info":[{"award-number":["2096"]}]},{"name":"Edmonton, Alberta, Canada, \u00d6sterreichische Krebshilfe Tyrol","award":["2096"],"award-info":[{"award-number":["2096"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD), is a liver condition that is linked to overweight, obesity, diabetes mellitus, and metabolic syndrome. Nonalcoholic steatohepatitis (NASH), or metabolic dysfunction-associated steatohepatitis (MASH), is a form of NAFLD\/MASLD that progresses over time. While steatosis is a prominent histological characteristic and recognizable grossly and microscopically, liver biopsies of individuals with NASH\/MASH may exhibit several other abnormalities, such as mononuclear inflammation in the portal and lobular regions, hepatocellular damage characterized by ballooning and programmed cell death (apoptosis), misfolded hepatocytic protein inclusions (Mallory\u2013Denk bodies, MDBs), megamitochondria as hyaline inclusions, and fibrosis. Ballooning hepatocellular damage remains the defining feature of NASH\/MASH. The fibrosis pattern is characterized by the initial expression of perisinusoidal fibrosis (\u201cchicken wire\u201d) and fibrosis surrounding the central veins. Children may have an alternative form of progressive NAFLD\/MASLD characterized by steatosis, inflammation, and fibrosis, mainly in Rappaport zone 1 of the liver acinus. To identify, synthesize, and analyze the scientific knowledge produced regarding the implications of using a score for evaluating NAFLD\/MASLD in a comprehensive narrative review. The search for articles was conducted between 1 January 2000 and 31 December 2023, on the PubMed\/MEDLINE, Scopus, Web of Science, and Cochrane databases. This search was complemented by a gray search, including internet browsers (e.g., Google) and textbooks. The following research question guided the study: \u201cWhat are the basic data on using a score for evaluating NAFLD\/MASLD?\u201d All stages of the selection process were carried out by the single author. Of the 1783 articles found, 75 were included in the sample for analysis, which was implemented with an additional 25 articles from references and gray literature. The studies analyzed indicated the beneficial effects of scoring liver biopsies. Although similarity between alcoholic steatohepatitis (ASH) and NASH\/MASH occurs, some patterns of hepatocellular damage seen in alcoholic disease of the liver do not happen in NASH\/MASH, including cholestatic featuring steatohepatitis, alcoholic foamy degeneration, and sclerosing predominant hyaline necrosis. Generally, neutrophilic-rich cellular infiltrates, prominent hyaline inclusions and MDBs, cholestasis, and obvious pericellular sinusoidal fibrosis should favor the diagnosis of alcohol-induced hepatocellular injury over NASH\/MASH. Multiple grading and staging methods are available for implementation in investigations and clinical trials, each possessing merits and drawbacks. The systems primarily used are the Brunt, the NASH CRN (NASH Clinical Research Network), and the SAF (steatosis, activity, and fibrosis) systems. Clinical investigations have utilized several approaches to link laboratory and demographic observations with histology findings with optimal platforms for clinical trials of rapidly commercialized drugs. It is promising that machine learning procedures (artificial intelligence) may be critical for developing new platforms to evaluate the benefits of current and future drug formulations.<\/jats:p>","DOI":"10.3390\/ijms25158462","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T16:14:58Z","timestamp":1722615298000},"page":"8462","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["NAFLD (MASLD)\/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2779-7879","authenticated-orcid":false,"given":"Consolato M.","family":"Sergi","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, University of Alberta, Edmonton, AB T6G 2B7, Canada"},{"name":"Children\u2019s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON K1H 8L1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1042\/CS20230522","article-title":"Inflammatory liver diseases and susceptibility to sepsis","volume":"138","author":"Lu","year":"2024","journal-title":"Clin. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Miao, L., Targher, G., Byrne, C.D., Cao, Y.Y., and Zheng, M.H. (2024). Current status and future trends of the global burden of MASLD. Trends Endocrinol. Metab., in press.","DOI":"10.1016\/j.tem.2024.02.007"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.5114\/amsad.2020.95884","article-title":"Usefulness of resveratrol supplementation in decreasing cardiometabolic risk factors comparing subjects with metabolic syndrome and healthy subjects with or without obesity: Meta-analysis using multinational, randomised, controlled trials","volume":"5","author":"Sergi","year":"2020","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: Updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4254\/wjh.v15.i2.123","article-title":"Metabolic-associated fatty liver disease: New nomenclature and approach with hot debate","volume":"15","author":"Fouad","year":"2023","journal-title":"World J Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106679","DOI":"10.1016\/j.phrs.2023.106679","article-title":"Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)","volume":"189","author":"Rizzo","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20420188241227766","DOI":"10.1177\/20420188241227766","article-title":"Liver Biopsy Handling of Metabolic-Associated Fatty Liver Disease (MAFLD): The Children\u2019s Hospital of Eastern Ontario grossing protocol","volume":"15","author":"Sergi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_10","first-page":"28","article-title":"Histopathology, grading and staging of nonalcoholic fatty liver disease","volume":"64","author":"Kleiner","year":"2018","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1097\/MPG.0000000000003249","article-title":"Safety, Feasibility, Yield, Diagnostic and Prognostic Implications of Transjugular Liver Biopsy in Children and Adolescents","volume":"73","author":"Lal","year":"2021","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e0033","DOI":"10.1097\/HC9.0000000000000033","article-title":"The nonalcoholic steatohepatitis extended hepatocyte ballooning score: Histologic classification and clinical significance","volume":"7","author":"Gill","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.humpath.2023.01.003","article-title":"Fatty liver disease that is neither metabolic nor alcoholic","volume":"141","author":"Allende","year":"2023","journal-title":"Hum. Pathol."},{"key":"ref_14","unstructured":"JBI (2015). Joanna Briggs Institute Reviewers\u2019 Manual: 2015, The Joanna Briggs Institute."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e000592","DOI":"10.1136\/bmjgast-2020-000592","article-title":"Scoping review of clinical practice guidelines on the management of benign liver tumours","volume":"8","author":"Haring","year":"2021","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: Towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int. J. Soc. Res. Methodol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1748-5908-5-69","article-title":"Scoping studies: Advancing the methodology","volume":"5","author":"Levac","year":"2010","journal-title":"Implement. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/HMER.S278076","article-title":"The Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics","volume":"13","author":"Neuberger","year":"2021","journal-title":"Hepat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1007\/s00261-020-02684-3","article-title":"Multiparametric DC. MR mapping in clinical decision-making for diffuse liver disease","volume":"45","author":"Lepe","year":"2020","journal-title":"Abdom. Radiol."},{"key":"ref_21","first-page":"30355","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: An individual patient data meta-analysis","volume":"15","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.7150\/thno.40249","article-title":"Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease","volume":"10","author":"Pirmoazen","year":"2020","journal-title":"Theranostics"},{"key":"ref_23","first-page":"CD011602","article-title":"Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease","volume":"3","author":"Pavlov","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: A prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3748\/wjg.v27.i7.609","article-title":"Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort","volume":"27","author":"Imajo","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/17474124.2017.1374852","article-title":"Elastography methods for the non-invasive assessment of portal hypertension","volume":"12","author":"Roccarina","year":"2018","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis","volume":"69","author":"Loomba","year":"2020","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100067","DOI":"10.1016\/j.jhepr.2020.100067","article-title":"Limitations of non-invasive tests for assessment of liver fibrosis","volume":"2","author":"Patel","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3350\/cmh.2019.0001n","article-title":"Application of transient elastography in nonalcoholic fatty liver disease","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100137","DOI":"10.1016\/j.jhepr.2020.100137","article-title":"Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease","volume":"2","author":"Sinha","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00239","DOI":"10.14309\/ctg.0000000000000239","article-title":"Breath biopsy assessment of liver disease using an exogenous volatile organic compound-toward improved detection of liver impairment","volume":"11","author":"Ferrandino","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00109-003-0508-x","article-title":"Iron overload in adult Hfe-deficient mice independent of changes in the steady-state expression of the duodenal iron transporters DMT1 and Ireg1\/ferroportin","volume":"82","author":"Herrmann","year":"2004","journal-title":"J. Mol. Med."},{"key":"ref_33","first-page":"1161","article-title":"No association between genetic hemochromatosis and alpha1-antitrypsin deficiency","volume":"24","author":"Fargion","year":"1996","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/liv.14773","article-title":"Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis","volume":"41","author":"Allende","year":"2021","journal-title":"Liver Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e0325","DOI":"10.1097\/HC9.0000000000000325","article-title":"Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study","volume":"8","author":"Sanyal","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/apt.17762","article-title":"Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum","volume":"59","author":"Palmer","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_37","unstructured":"Kudaravalli, P., and John, S. (2024). Nonalcoholic Fatty Liver, StatPearls."},{"key":"ref_38","unstructured":"Antunes, C., Azadfard, M., Hoilat, G.J., and Gupta, M. (2024). Fatty Liver, StatPearls."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Lahiri, P., Schmidt, V., Smole, C., Kufferath, I., Denk, H., Strnad, P., R\u00fclicke, T., Fr\u00f6hlich, L.F., and Zatloukal, K. (2016). p62\/Sequestosome-1 Is Indispensable for Maturation and Stabilization of Mallory-Denk Bodies. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161083"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41575-023-00843-7","article-title":"Digital pathology for nonalcoholic steatohepatitis assessment","volume":"21","author":"Sanyal","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-023-08031-y","article-title":"A Machine Learning Method to Identify the Risk Factors for Liver Fibrosis Progression in Nonalcoholic Steatohepatitis","volume":"68","author":"Suarez","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jceh.2022.12.003","article-title":"Automated Segmentation and Morphological Characterization of Hepatic Steatosis and Correlation with Histopathology","volume":"13","author":"Esparza","year":"2023","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Iyer, J.S., Pokkalla, H., Biddle-Snead, C., Carrasco-Zevallos, O., Lin, M., Shanis, Z., Le, Q., Juyal, D., Pouryahya, M., and Pedawi, A. (2023). AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trials. medRxiv.","DOI":"10.1101\/2023.04.20.23288534"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/liv.15571","article-title":"Hepatocytic ballooning in non-alcoholic steatohepatitis: Dilemmas and future directions","volume":"43","author":"Li","year":"2023","journal-title":"Liver Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101368","DOI":"10.1016\/j.jceh.2024.101368","article-title":"Post-Liver Transplant Metabolic Syndrome","volume":"14","author":"Choudhury","year":"2024","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.62347\/KMSA5983","article-title":"Non-alcoholic fatty liver disease: Pathogenesis and models","volume":"16","author":"Zhong","year":"2024","journal-title":"Am. J. Transl. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.34172\/aim.2024.04","article-title":"Increasing Prevalence and High Survival Rate of Liver Transplanted Patients with NASH and PSC Cirrhosis","volume":"27","author":"Khajehahmadi","year":"2024","journal-title":"Arch. Iran. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e0352","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013\u20132022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol Commun"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"101281","DOI":"10.1016\/j.jceh.2023.09.002","article-title":"Post-transplant Non-alcoholic Fatty Liver Disease and Metabolic Syndrome After Living Donor Liver Transplantation in Indians","volume":"14","author":"Choudhary","year":"2024","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/HEP.0000000000000545","article-title":"A global action agenda for turning the tide on fatty liver disease","volume":"79","author":"Lazarus","year":"2024","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2174\/1573396319666230403121805","article-title":"Metabolic Associated Fatty Liver Disease in Children and Adolescents: Mechanisms of a Silent Epidemic and Therapeutic Options","volume":"20","author":"Mosca","year":"2024","journal-title":"Curr. Pediatr. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Bahitham, W., Alghamdi, S., Omer, I., Alsudais, A., Hakeem, I., Alghamdi, A., Abualnaja, R., Sanai, F.M., Rosado, A.S., and Sergi, C.M. (2024). Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030550"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/PAS.0000000000000802","article-title":"Donor Liver Small Droplet Macrovesicular Steatosis Is Associated With Increased Risk for Recipient Allograft Rejection","volume":"41","author":"Choi","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jhep.2010.11.021","article-title":"Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease","volume":"55","author":"Tandra","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/hep.23784","article-title":"Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease","volume":"52","author":"Clark","year":"2010","journal-title":"Hepatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/01.MP.0000019579.30842.96","article-title":"Kupffer cell aggregation and perivenular distribution in steatohepatitis","volume":"15","author":"Lefkowitch","year":"2002","journal-title":"Mod. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/hep.22724","article-title":"Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network","volume":"49","author":"Brunt","year":"2009","journal-title":"Hepatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.26937","article-title":"The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease","volume":"59","author":"Gadd","year":"2014","journal-title":"Hepatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28-year follow-up","volume":"51","author":"Askling","year":"2010","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Haflidadottir, S., Jonasson, J.G., Norland, H., Einarsdottir, S.O., Kleiner, D.E., Lund, S.H., and Bjornsson, E.S. (2014). Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol., 14.","DOI":"10.1186\/1471-230X-14-166"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1665-2681(19)31748-X","article-title":"NASH and cryptogenic cirrhosis: A histological analysis","volume":"8","author":"Caldwell","year":"2009","journal-title":"Ann. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.20842","article-title":"Histopathology of pediatric nonalcoholic fatty liver disease","volume":"42","author":"Schwimmer","year":"2005","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1053\/j.gastro.2008.08.050","article-title":"Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis","volume":"135","author":"Patton","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/ajg.2010.152","article-title":"Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease","volume":"105","author":"Patton","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.cgh.2017.02.030","article-title":"In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis","volume":"16","author":"Africa","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PDM.0b013e31817cfd4b","article-title":"Diagnosis of hepatic iron overload: A family study illustrating pitfalls in diagnosing hemochromatosis","volume":"18","author":"Schranz","year":"2009","journal-title":"Diagn. Mol. Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/s-2007-970591","article-title":"An unusual case of intrauterine symptomatic neonatal liver failure","volume":"220","author":"Keller","year":"2008","journal-title":"Klin. Padiatr."},{"key":"ref_70","first-page":"699","article-title":"Hepatic failure with neonatal tissue siderosis of hemochromatotic type in an infant presenting with meconium ileus. Case report and differential diagnosis of the perinatal iron storage disorders","volume":"197","author":"Sergi","year":"2001","journal-title":"Pathol. Res. Pr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"(2003). Nonalcoholic steatohepatitis clinical research network. Hepatology, 37, 244.","DOI":"10.1002\/hep.510370203"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: Current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","article-title":"Genetic factors that affect risk of alcoholic and nonalco-holic fatty liver disease","volume":"150","author":"Anstee","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","article-title":"Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond","volume":"158","author":"Krawczyk","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1073\/pnas.1003585107","article-title":"A feed-forward loop amplifies nutritional regulation of PNPLA3","volume":"107","author":"Huang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.1074\/jbc.M116.719955","article-title":"Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins","volume":"291","author":"Smagris","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Speliotes, E.K., Yerges-Armstrong, L.M., Wu, J., Hernaez, R., Kim, L.J., Palmer, C.D., Gudnason, V., Eiriksdottir, G., Garcia, M.E., and Launer, L.J. (2011). Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet., 7.","DOI":"10.1371\/journal.pgen.1001324"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1600-0676.1992.tb01064.x","article-title":"Genetic variants of alpha-1-antitrypsin (AAT)","volume":"12","author":"Fabbretti","year":"1992","journal-title":"Liver"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Sergi, C.M. (2021). Carcinoma of the Liver in Children and Adolescents. Liver Cancer, Exon Publications.","DOI":"10.36255\/exonpublications.livercancer.2021.ch1"},{"key":"ref_87","first-page":"130","article-title":"Immunohistochemical and genetic characterization of the M Cagliari alpha-1-antitrypsin molecule (M-like alpha-1-antitrypsin deficiency)","volume":"70","author":"Sergi","year":"1994","journal-title":"Lab. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/gutjnl-2018-316228","article-title":"Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis","volume":"68","author":"Strnad","year":"2019","journal-title":"Gut"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease","volume":"378","author":"Cheng","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MOG.0000000000000927","article-title":"Advances in the genetics of nonalcoholic fatty liver disease","volume":"39","author":"Ajmera","year":"2023","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41588-023-01497-6","article-title":"Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease","volume":"55","author":"Chen","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/liv.15857","article-title":"Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome","volume":"44","author":"Dutta","year":"2024","journal-title":"Liver Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100693","DOI":"10.1016\/j.jhepr.2023.100693","article-title":"Hepatocyte mARC1 promotes fatty liver disease","volume":"5","author":"Lewis","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5009\/gnl230044","article-title":"Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort","volume":"18","author":"Park","year":"2024","journal-title":"Gut Liver"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cld.2023.01.006","article-title":"Genetic Markers Predisposing to Nonalcoholic Steatohepatitis","volume":"27","author":"Sohal","year":"2023","journal-title":"Clin. Liver Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.4081\/jphr.2020.1952","article-title":"Mathematical models in nursing research","volume":"9","author":"Rea","year":"2020","journal-title":"J. Public Health Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5539\/gjhs.v5n6p112","article-title":"Bridging the gap between the technological singularity and mainstream medicine: Highlighting a course on technology and the future of medicine","volume":"5","author":"Solez","year":"2013","journal-title":"Glob. J. Health Sci."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Sergi, C., and Mikuz, G. (2008). External quality assurance as a revalidation method for pathologists in pediatric histopathology: Comparison of four international programs. BMC Clin. Pathol., 8.","DOI":"10.1186\/1472-6890-8-11"},{"key":"ref_99","unstructured":"Dragan, C. (2019). Digital Pathology: The Time Is Now to Bridge the Gap between Medicine and Technological Singularity. Interactive Multimedia, IntechOpen. Chapter 9."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/HEP.0000000000000723","article-title":"Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis","volume":"80","author":"Ratziu","year":"2024","journal-title":"Hepatology"},{"key":"ref_101","unstructured":"Pan, S.J., Kwok, J.T., and Yang, Q. (2008, January 13\u201317). Transfer learning via dimensionality reduction. Proceedings of the 23rd National Conference on Artificial Intelligence\u2014Volume 2, Chicago, IL, USA."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Luo, Z., Wang, R., Sun, Y., Liu, J., Chen, Z., and Zhang, Y.J. (2024). Interpretable feature extraction and dimensionality reduction in ESM2 for protein localization prediction. Brief. Bioinform., 25.","DOI":"10.1093\/bib\/bbad534"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11023-020-09517-8","article-title":"The Ethics of AI Ethics: An Evaluation of Guidelines","volume":"30","author":"Hagendorff","year":"2020","journal-title":"Minds Mach."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/03008916221146208","article-title":"Demystifying neuroblastoma malignancy through fractal dimension, entropy, and lacunarity","volume":"109","author":"Donato","year":"2023","journal-title":"Tumori"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/15\/8462\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:29:12Z","timestamp":1760110152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/15\/8462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":104,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25158462"],"URL":"https:\/\/doi.org\/10.3390\/ijms25158462","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]}}}